KRM-III

• Description :

  KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC50 of ~5 μM. Anti-inflammatory activity[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H319

• Target :

  Nuclear Factor of activated T Cells (NFAT)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/krm-iii.html

• Concentration :

  10mM

• Purity :

  98.08

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  S=C1NC(C2=CC=CC=C2)=CN1C3=CC=CC=C3

• Molecular Formula :

  C15H12N2S

• Molecular Weight :

  252.33

• Precautions :

  H319

• References & Citations :

  [1]Eun Joo Jung, et al. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. J Pharmacol Exp Ther. 2009 Dec;331 (3) :1005-13.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [79220-94-3]